Related references
Note: Only part of the references are listed.T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study
Parakkal Deepak et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Sixty-year Study of Incidence of Childhood Ulcerative Colitis Finds Eleven-fold Increase Beginning in 1990s
Vered Schildkraut et al.
INFLAMMATORY BOWEL DISEASES (2013)
Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options
Corey A. Siegel
GUT (2012)
The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006
Lisa J. Herrinton et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Perceived and Actual Quality of Life With Ulcerative Colitis: A Comparison of Medically and Surgically Treated Patients
Akbar K. Waljee et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Proximity to Disease and Perception of Utility: Physicians' vs Patients' Assessment of Treatment Options for Ulcerative Colitis
Lindsay Kennedy Brown et al.
DISEASES OF THE COLON & RECTUM (2011)
Individual Health Discount Rate in Patients with Ulcerative Colitis
Akbar K. Waljee et al.
INFLAMMATORY BOWEL DISEASES (2011)
Eliciting Benefit-Risk Preferences and Probability-Weighted Utility Using Choice-Format Conjoint Analysis
George Van Houtven et al.
MEDICAL DECISION MAKING (2011)
Conjoint Analysis Applications in Health-a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
John F. P. Bridges et al.
VALUE IN HEALTH (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Multiple sclerosis patients' benefit-risk preferences: Serious adverse event risks versus treatment efficacy
F. Reed Johnson et al.
JOURNAL OF NEUROLOGY (2009)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Crohn's disease patients' risk-benefit preferences:: Serious adverse event risks versus treatment efficacy
F. Reed Johnson et al.
GASTROENTEROLOGY (2007)
A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
Chinyu Su et al.
GASTROENTEROLOGY (2007)
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
GR Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
A Kandiel et al.
GUT (2005)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Mesalamine derivatives in the treatment of Crohn's disease
LE Harrell et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2004)
Optimal design for multinomial choice experiments
BJ Kanninen
JOURNAL OF MARKETING RESEARCH (2002)
Developments in non-expected utility theory: The hunt for a descriptive theory of choice under risk
C Starmer
JOURNAL OF ECONOMIC LITERATURE (2000)
Share Paper
